MedTrace Logo

A Phase IIII Study of AL8326 in Small Cell Lung Cancer

NCT06247605 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 243

Last updated 2024-02-08

No results posted yet for this study

Summary

This is a multicenter, randomized, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of AL8326 tablets in small cell lung cancer (SCLC) patients with disease progression or recurrence after receiving at least second-line treatment regimens.

Conditions

  • Small Cell Lung Carcinoma

Interventions

DRUG

AL8326 tablets

10mg/tablet, Oral administration, once daily.

DRUG

placebo

Oral administration, once daily.

Sponsors & Collaborators

  • Advenchen Laboratories Nanjing Ltd.

    lead INDUSTRY

Principal Investigators

  • Ying Cheng · Jilin Provincial Tumor Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-26
Primary Completion
2028-07-31
Completion
2029-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06247605 on ClinicalTrials.gov